GlassScriptPhysician profile
Christina E Rosengren
NPI 1790019941
$2,679.31
in general payments reported to CMS, 2019-2025
24 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $635 · 2023: $35.66 · 2024: $256 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.13 |
| Travel and Lodging | $969.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,457.24 | 2021-2025 | Venaseal |
| Allergan, INC. | $227.06 | 2021 | |
| Inari Medical, INC. | $130.25 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tactile Systems Technology INC | $123.49 | 2025 | Nimbl, Flexitouch Plus |
| Abbott Laboratories | $115.94 | 2021-2024 | Esprit |
| Pfizer INC. | $112.36 | 2025 | |
| Lilly USA, LLC | $62.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $59.65 | 2021-2025 | |
| Pacira Therapeutics, INC. | $46.98 | 2021 | |
| Koya Medical, INC. | $45.70 | 2025 | Koya Medical, Dayspring |
| Arbor Pharmaceuticals, INC. | $32.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.82 | 2025 | Camzyos |
| Biodelivery Sciences International, INC. | $31.47 | 2021 | |
| Collegium Pharmaceutical, INC. | $26.60 | 2021 | |
| Springworks Therapeutics, INC. | $25.01 | 2024 | Ogsiveo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $22.71 | 2025 | Rotarexs 6 F X 135 Cm |
| Incyte Corporation | $21.74 | 2023 | Jakafi |
| Vanda Pharmaceuticals INC. | $19.58 | 2021 | |
| Merck Sharp & Dohme LLC | $17.73 | 2024 | Keytruda |
| Abbvie INC. | $17.18 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.04 | 2025 | Amvuttra |
| Sobi, INC | $13.92 | 2023 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Acacia Pharma INC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Rosengren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.